PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Cost reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive advantage potential.
12.50%
Growth of 12.50% versus flat Biotechnology gross profit. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
37.48%
R&D change of 37.48% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
21.30%
G&A change of 21.30% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
100.00%
Marketing expense change of 100.00% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
No Data
No Data available this quarter, please select a different quarter.
32.37%
Operating expenses growth exceeding 1.5x Biotechnology median of 0.01%. Jim Chanos would check for waste.
29.39%
Total costs change of 29.39% versus flat Biotechnology costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
-30.36%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-29.39%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
14.89%
Other expenses change of 14.89% versus flat Biotechnology. Walter Schloss would verify control.
-30.95%
Pre-tax income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-30.95%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-22.58%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-22.58%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
7.95%
Share count reduction below 50% of Biotechnology median of 0.55%. Jim Chanos would check for issues.
7.95%
Diluted share reduction below 50% of Biotechnology median of 0.52%. Jim Chanos would check for issues.